peoplePerson
Dae Ho Lee
Dae Ho Lee is a thoracic oncologist behind Korean participation in the EGFR, ALK, and MET inhibitor trials that shaped lung cancer care.
Dae Ho Lee has led and co-led NSCLC trials at Asan Medical Center including third-generation EGFR inhibitor studies and MET-directed therapies, and contributes to Korean lung cancer treatment guidelines.
Role
Professor of Medical Oncology; thoracic oncology
Institution
Specialisms
Lung cancerEGFR and ALK inhibitorsClinical trials
| Title | Journal | Year |
|---|---|---|
| Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC (MARIPOSA) | NEJM | 2024 |
Pages like this
not linked directly; found by shared links- PairingAmivantamab + lazertinib (first-line EGFR NSCLC)
Shares Lazertinib, MARIPOSA, Amivantamab, MET.
- PersonByoung Chul Cho
Shares Lazertinib, MARIPOSA, Amivantamab, MET.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares Amivantamab, MET, Osimertinib, EGFR.
- TermEGFR exon 19 deletion & L858R
Shares Lazertinib, Amivantamab, Osimertinib, EGFR.
- IdeaAdd the second drug on day one when the escape route is predictable
Shares Amivantamab, MET, Osimertinib, EGFR.
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- InstitutionShanghai Chest Hospital
Shares Amivantamab, MET, Osimertinib, EGFR.
- TermMET amplification (bypass resistance)
Shares Amivantamab, MET, EGFR, Non-small-cell lung cancer.